Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

Phase 2 Not yet recruiting

700 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Breast

Triple Negative Breast Neoplasms

NCT05954442 2024-01-16

BCTOP-T-M03

Phase 3 Recruiting

203 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01931163 2021-07-20

NECTAR

Phase 2 Completed

24 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01031446 2018-08-31

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

55 enrolled 12 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02616848 2015-11-30

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Phase 1 Unknown

1 enrolled

Breast

Triple Negative Breast Neoplasms

NCT00930930 2015-05-07

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Completed

145 enrolled 10 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Clinical Trials

POLARIS

EVOLVE-BDT

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

BCTOP-T-M03

FUTURE

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

NECTAR

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer